Suppr超能文献

静脉-静脉与静脉-动脉体外膜肺氧合治疗儿科非心源性脓毒症患者的生存改善:体外生命支持组织登记研究。

Improved survival in venovenous vs venoarterial extracorporeal membrane oxygenation for pediatric noncardiac sepsis patients: a study of the Extracorporeal Life Support Organization registry.

机构信息

Division of Pediatric Surgery, University of Kentucky, Lexington, Kentucky 40536-0298, USA.

出版信息

J Pediatr Surg. 2012 Jan;47(1):63-7. doi: 10.1016/j.jpedsurg.2011.10.018.

Abstract

BACKGROUND/PURPOSE: There are few studies comparing venoarterial (VA) and venovenous (VV) extracorporeal membrane oxygenation (ECMO) in pediatric noncardiac sepsis patients.

METHODS

Following approval, we reviewed the Extracorporeal Life Support Organization registry data from 1990 to 2008 for patients 0 to 18 years with a diagnosis of sepsis and without diagnosis of congenital heart disease. Survival to discharge was compared between VA and VV ECMO using χ(2) analysis and multivariable logistic regression.

RESULTS

Four thousand three hundred thirty-two ECMO runs were reviewed, 3256 VA (75%) and 1076 VV (25%). A majority of VA modality was noted in each decade studied. Overall survival was 68% and was higher in VV (79%) than in VA ECMO (64%, P < .001). Survival decreased with increasing age (73% in newborns ≤ 1 month, 40% in children 1 month to 12 years, and 32% in adolescents >12 years, P < .001). VA ECMO had increased mortality risk after adjustment for age, use of vasoactive agents, and advanced respiratory support (odds ratio, 2.06; 95% confidence interval, 1.74-2.44; P < .001).

CONCLUSIONS

These data demonstrate improved survival in VV vs. VA ECMO in select pediatric septic patients without congenital heart disease. When technically feasible, physicians should consider VV ECMO as first therapeutic choice in this patient population.

摘要

背景/目的:在儿科非心脏感染性休克患者中,比较动静脉(VA)和静脉-静脉(VV)体外膜肺氧合(ECMO)的研究很少。

方法

在获得批准后,我们回顾了 1990 年至 2008 年期间,体外生命支持组织登记处的患者数据,这些患者的诊断为感染性休克且无先天性心脏病。使用 χ(2)分析和多变量逻辑回归比较 VA 和 VV ECMO 患者的出院生存率。

结果

共回顾了 4332 次 ECMO 运行,3256 次 VA(75%)和 1076 次 VV(25%)。在每个研究的十年中,VA 模式都占大多数。总体生存率为 68%,VV(79%)高于 VA ECMO(64%,P <.001)。生存率随年龄增加而降低(新生儿≤1 个月为 73%,1 个月至 12 岁儿童为 40%,12 岁以上青少年为 32%,P <.001)。VA ECMO 在调整年龄、血管活性药物使用和高级呼吸支持后,死亡率风险增加(优势比,2.06;95%置信区间,1.74-2.44;P <.001)。

结论

这些数据表明,在没有先天性心脏病的选择儿科感染性休克患者中,VV 比 VA ECMO 具有更好的生存率。在技术上可行的情况下,医生应考虑在该患者人群中,将 VV ECMO 作为首选治疗方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验